[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342000-105":59,"doc-detail-342000-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhanced-docetaxel-therapeutic-effect-using-dual-targeted-srl-2-and-ta1-aptamer-conjugated-micelles-in-inhibition-balbc-mice-breast-cancer-model","Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model","","The work develops dual pH/redox responsive docetaxel (DTX)-loaded PBAS micelles decorated with a chimeric peptide and the TA1 aptamer to improve targeted delivery against breast cancer. In vitro and in vivo results show minimal circulation detection, followed by activation in tumor microenvironment conditions (high GSH, low pH) that disrupts nanoparticles and amplifies drug release (~70% at 24 h). MST@PBAS micelles exhibit lower IC50 than free DTX after 48 h and induce stronger cytotoxicity with increased early apoptosis, while dual targeting increases tumor uptake and growth inhibition using reduced therapeutic dose.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhanced-docetaxel-therapeutic-effect-using-dual-targeted-srl-2-and-ta1-aptamer-conjugated-micelles-in-inhibition-balbc-mice-breast-cancer-model/342000/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhanced-docetaxel-therapeutic-effect-using-dual-targeted-srl-2-and-ta1-aptamer-conjugated-micelles-in-inhibition-balbc-mice-breast-cancer-model/342000.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do the dual targeted SRL-2 and TA1 aptamer micelles improve docetaxel delivery?","Question",{"text":112,"@type":113},"They are designed to remain undetectable in circulation and then respond to tumor microenvironment conditions (high GSH and low pH). Disruption under these conditions enhances DTX release and increases targeting through two ligands.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What level of docetaxel release is reported after tumor microenvironment exposure?",{"text":117,"@type":113},"The described system releases around 70% of DTX at 24 hours after exposure to the tumor microenvironment conditions.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the nano-formulated micelles perform versus free docetaxel in cell studies and apoptosis?",{"text":121,"@type":113},"Nano-formulated DTX shows cytotoxicity about 5-fold stronger than free DTX, and cell cycle results indicate an increased sub-G1 population. Micelles also produce higher early apoptosis (59.8%) compared with free DTX (44.7%).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342000,1790396793,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEnhanced docetaxel therapeutic effect using dual targeted SRL- 2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model  \nYasamin Davatgaran Taghipour1,9, Amir Zarebkohan2􀀍, Roya Salehi1,3􀀍, Mehdi Talebi4, Reza Rahbarghazi5, Monireh Khordadmehr6, Sharareh Khavandkari7, Fahimeh Badparvar8 & Vladimir P. Torchilin9  \nEffective targeting and delivery of large amounts of medications into the cancer cells enhance their therapeutic efficacy through saturation of cellular defensive mechanisms, which is the most privilege of nano drug delivery systems (NDDS) compared to traditional approaches. Herein, we designed dual-pH/ redox responsive DTX-loaded poly (β-amino ester) (PBAS) micelles decorated with a chimeric peptide and TA1 aptamer. In vitro and in vivo results demonstrated that the designed nanoplatform possessed an undetectable nature in the blood circulation, but after exposure to the tumor microenvironment (TME) of 4T1 breast cancer, it suddenly changed into dual targeting nanoparticles (NPs) (containing two ligands, SRL-2 and TA1 aptamer). The dual targeting NPs destruction in the high GSH and low pH conditions of the cancer cells led to amplified DTX release (around 70% at 24 h). The IC50 value of DTX-loaded MMP-9 sensitive heptapeptide/TA1 aptamer-modified poly (β-amino ester) (MST@ PBAS) micelles and free DTX after 48 h of exposure was determined to be 1.5 µg/ml and 7.5 µg/ml, respectively. The nano-formulated DTX exhibited cytotoxicity that was 5-fold stronger than free DTX (Pvalue˂0.001). Cell cycle assay test results showed that following exposure to MST@PBAS micelles, a considerable rise in the sub G1 population (48%) suggested that apoptosis by cell cycle arrest had occurred. DTX-loaded MST@PBAS micelles revealed significantly higher (Pvalue ˂ 0.001)  \nlevels of early apoptosis (59.8%) than free DTX (44.7%) . Interestingly, in vitro uptake studies showed a significantly higher TME accumulation of dual targeted NPs (6-fold) compared to single targeted NPs (Pvalue \u003C 0.001) which further confirmed by in vivo biodistribution and fluorescent TUNELassay experiments. NPs treated groups demonstrated notable tumor growth inhibition in 4T1 tumor bearing Balb/c mice by only 1/10th ofthe DTX therapeutic dose (TD) as a drug model. In conclusion, cleverly designed nanostructures here demonstrated improved anticancer effects by enhancing tumor targeting, delivering chemotherapeutic agents more accurately, promoting drug release, reducing the therapeutic dosage, and lowering side effects of anticancer drugs.  \nKeywords Drug resistance, DTX, Delivery, Smart, GSH/pH responsive, TA1 aptamer, SRL-2  \n1Department of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz 516661-4733, Iran. 2Drug Applied Research Center, Department of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz 516661-4733, Iran. 3Clinical Research Development Unite of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz 51666-18559, Iran. 4Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 5Stem Cell Research Center, Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 6Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran. 7Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. 8Department of Organic Chemistry, Faculty of Chemistry, Urmia University, Urmia, Iran. 9Center for Pharmaceutical Biotechnology and Nanomedicine, Department of Chemical Engineering, Northeastern University, Boston, USA. 􀀍 [email: zarebkohana@tbzmed.ac.ir](email: zarebkohana@tbzmed.ac.ir); [salehiro@tbzmed.ac.ir](salehiro@tbzmed.ac.ir)  ","cbCaikFpXojMJ48v","https://ap.wps.com/l/cbCaikFpXojMJ48v","pdf",2219839,11,"English","# Introduction\n## Chemotherapy adverse effects and lack of specificity\n## Drug resistance mechanisms in cancer\n# Methods and nanoplatform design\n## Dual pH/redox responsive DTX-loaded PBAS micelles\n## Ligand decoration with SRL-2 and TA1 aptamer\n# Results\n## Tumor microenvironment-triggered nanoparticle disruption and drug release\n## IC50 and cytotoxicity compared with free DTX\n## Cell cycle effects and apoptosis induction\n## Uptake, biodistribution, and tumor growth inhibition\n# Conclusion","[{\"question\":\"How do the dual targeted SRL-2 and TA1 aptamer micelles improve docetaxel delivery?\",\"answer\":\"They are designed to remain undetectable in circulation and then respond to tumor microenvironment conditions (high GSH and low pH). Disruption under these conditions enhances DTX release and increases targeting through two ligands.\"},{\"question\":\"What level of docetaxel release is reported after tumor microenvironment exposure?\",\"answer\":\"The described system releases around 70% of DTX at 24 hours after exposure to the tumor microenvironment conditions.\"},{\"question\":\"How do the nano-formulated micelles perform versus free docetaxel in cell studies and apoptosis?\",\"answer\":\"Nano-formulated DTX shows cytotoxicity about 5-fold stronger than free DTX, and cell cycle results indicate an increased sub-G1 population. Micelles also produce higher early apoptosis (59.8%) compared with free DTX (44.7%).\"}]","Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model | PDF",1790044703,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e627d60d93f9129c160df2127b1c48eb.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f81d7107035d5e54666bfcb745d631fe.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e095ea6f6008731bff9003fb25302157.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4e51e057dac9e5ac114d69e5af556b5.webp",980,1287]